

Han Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3122671/publications.pdf>

Version: 2024-02-01

9
papers

608
citations

1307594

7
h-index

1720034

7
g-index

9
all docs

9
docs citations

9
times ranked

1164
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	9.4	58
2	Loss of <i>TSC1/TSC2</i> sensitizes immune checkpoint blockade in non-small cell lung cancer. <i>Science Advances</i> , 2022, 8, eabi9533.	10.3	16
3	Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 371-380.	6.3	153
4	Response to Cottu, Bozec, Basse, and Paoletti. <i>Journal of the National Cancer Institute</i> , 2021, 113, 344-345.	6.3	0
5	Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021, 40, 2817-2829.	5.9	26
6	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 503-514.	13.2	72
7	Response to Huang, Rivero-Hinojosa, Ma, et al. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1111-1112.	6.3	0
8	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 37, 37-54.e9.	16.8	138
9	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Pozotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	16.8	145